Carlos M Telleria
Overview
Explore the profile of Carlos M Telleria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Mokbel N, Goyeneche A, Prakash R, Forgie B, Abdalbari F, Zeng X, et al.
Biochem Biophys Rep
. 2024 Oct;
40:101838.
PMID: 39469046
High-grade serous cancer is the most common type of ovarian cancer and is usually diagnosed at advanced stages with high mortality due to recurrence and eventual resistance to standard platinum...
2.
Martinez-Jaramillo E, Jamali F, Abdalbari F, Abdulkarim B, Jean-Claude B, Telleria C, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001381
Glioblastoma (GBM) is the most prevalent and advanced malignant primary brain tumor in adults. GBM frequently harbors epidermal growth factor receptor (EGFR) wild-type () gene amplification and/or activating mutation. EGFR-driven...
3.
Forgie B, Prakash R, Goyeneche A, Telleria C
Discov Oncol
. 2024 Jan;
15(1):5.
PMID: 38180601
In the field of experimental therapeutics for oncology purposes researchers are continuously evaluating the toxicity of novel treatment approaches against cancer cells. Within this topic of research, it is highly...
4.
Conforti R, Delsouc M, Zorychta E, Telleria C, Casais M
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139406
Copper (Cu) is an essential micronutrient for the correct development of eukaryotic organisms. This metal plays a key role in many cellular and physiological activities, including enzymatic activity, oxygen transport,...
5.
Abdalbari F, Martinez-Jaramillo E, Forgie B, Tran E, Zorychta E, Goyeneche A, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958311
High-grade serous ovarian cancer (HGSOC) accounts for 70% of ovarian cancer cases, and the survival rate remains remarkably low due to the lack of effective long-term consolidation therapies. Clinical remission...
6.
Prakash R, Telleria C
Oncoscience
. 2023 Jun;
10:14-19.
PMID: 37273928
Cancer cell repopulation after therapy is a phenomenon that leads to therapeutic failure with the consequent relapse of the disease. The process is understudied and mechanisms need to be uncovered....
7.
Forgie B, Prakash R, Telleria C
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499737
Cisplatin (CDDP), carboplatin (CP), and oxaliplatin (OXP) are three platinating agents clinically approved worldwide for use against a variety of cancers. They are canonically known as DNA damage inducers; however,...
8.
Ritch S, Noman A, Goyeneche A, Telleria C
Cancer Cell Int
. 2022 Dec;
22(1):397.
PMID: 36494669
Background: Simplistic two-dimensional (2D) in vitro assays have long been the standard for studying the metastatic abilities of cancer cells. However, tri-dimensional (3D) organotypic models provide a more complex environment,...
9.
Ritch S, Telleria C
Front Endocrinol (Lausanne)
. 2022 May;
13:886533.
PMID: 35574025
Epithelial ovarian cancer (EOC) is considered the deadliest gynecological disease and is normally diagnosed at late stages, at which point metastasis has already occurred. Throughout disease progression, EOC will encounter...
10.
Abdalbari F, Telleria C
Discov Oncol
. 2022 Feb;
12(1):42.
PMID: 35201489
Advanced stages of cancer are highly associated with short overall survival in patients due to the lack of long-term treatment options following the standard form of care. New options for...